Cangrelor: Phase III data

The double-blind, international Phase III CHAMPION PCI trial in 8,716 patients undergoing PCI showed that cangrelor missed the composite primary endpoint of reducing death from any cause, MI or ischemia-driven revascularization at 48 hours vs. Plavix clopidogrel (7.5% vs. 7.1%, p=0.59). Cangrelor also was not superior to Plavix on the composite endpoint at 30 days. Data were presented at American Heart Association Meeting in Orlando and published in the New England Journal of Medicine. ...